HSF2 and neoplasm: In vivo, therapeutic immunization with the minimal epitope Hsf2 p.K72N elicited an enrichment of 47BE7+ CD8+ T cells amongst tumour-infiltrating lymphocytes (TILs) (Supplementary Fig. 6a) and delayed tumour growth (Fig. 4a, b).